Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)

Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy

(2013) Brian S. Choi et al.   LEUKEMIA & LYMPHOMA

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

(2013) Ralph Boccia et al.   SUPPORTIVE CARE IN CANCER

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

(2012) M. Aapro et al.   ANNALS OF ONCOLOGY

Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting

(2012) Camilo Rojas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy

(2012) F. Longo et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy

(2012) Rahat Noor et al.   SUPPORTIVE CARE IN CANCER

Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting

(2011) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

(2011) Kenjiro Aogi et al.   SUPPORTIVE CARE IN CANCER

Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study

(2011) C. Yavas et al.   SUPPORTIVE CARE IN CANCER

Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy

(2011) Bruce Feinberg et al.   SUPPORTIVE CARE IN CANCER

Electrocardiographic findings of palonosetron in cancer patients

(2011) Guzin Gonullu et al.   SUPPORTIVE CARE IN CANCER

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

(2010) M. Aapro et al.   ANNALS OF ONCOLOGY

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

(2010) Rudolph M Navari   Future Oncology

The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo

(2010) C. Rojas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial

(2010) Luigi Celio et al.   SUPPORTIVE CARE IN CANCER

Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor

(2009) Camilo Rojas et al.   ANESTHESIA AND ANALGESIA

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

(2009) Mitsue Saito et al.   LANCET ONCOLOGY